Modern Therapy of Acute Lymphoblastic Leukemia

被引：380

作者：

Bassan, Renato ^{[1
]}

Hoelzer, Dieter

机构：

[1] Osped Riuniti Bergamo, I-24128 Bergamo, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 05期

关键词：

STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOCYTIC-LEUKEMIA; 1ST COMPLETE REMISSION; BONE-MARROW-TRANSPLANTATION; FRONT-LINE THERAPY; TERM-FOLLOW-UP; ADULT PATIENTS; STANDARD-RISK; HYPER-CVAD;

D O I：

10.1200/JCO.2010.30.1382

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics. These data, along with the kinetics of response to early treatment, help establish the individual risk class with considerable accuracy, and support risk-specific treatments that should warrant optimal results with as little as possible nonrelapse mortality. Modern first-line therapy consists of standard-and high-dose chemotherapy (increasingly inspired to pediatric principles), hematopoietic stem-cell transplantation, and new targeted therapy, all integrated with the analysis of prognostic factors and the study of subclinical residual disease for key therapeutic decisions. These changes are improving long-term outcome, which in ongoing studies is expected close to 50% or greater. J Clin Oncol 29:532-543. (C) 2011 by American Society of Clinical Oncology

引用

页码：532 / 543

页数：12

共 84 条

[71] Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen [J].

Storring, John M. ;

Minden, Mark D. ;

Kao, Susan ;

Gupta, Vikas ;

Schuh, Andre C. ;

Schimmer, Aaron D. ;

Yee, Karen W. L. ;

Kamel-Reid, Suzanne ;

Chang, Hong ;

Lipton, Jeffrey H. ;

Messner, Hans A. ;

Xu, Wei ;

Brandwein, Joseph M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (01) :76-85

[72] NMR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia [J].

Tafuri, A ;

Gregorj, C ;

Petrucci, MT ;

Ricciardi, MR ;

Mancini, M ;

Cimino, G ;

Mecucci, C ;

Tedeschi, A ;

Fioritoni, G ;

Ferrara, F ;

Di Raimondo, F ;

Gallo, E ;

Liso, V ;

Fabbiano, F ;

Cascavilla, N ;

Pizzolo, G ;

Camera, A ;

Pane, F ;

Lanza, F ;

Cilloni, D ;

Annino, L ;

Vitale, A ;

Vegna, ML ;

Vignetti, M ;

Foà, R ;

Mandelli, F .

BLOOD, 2002, 100 (03) :974-981

[73] Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study [J].

Takeuchi, J ;

Kyo, T ;

Naito, K ;

Sao, H ;

Takahashi, M ;

Miyawaki, S ;

Kuriyama, K ;

Ohtake, S ;

Yagasaki, F ;

Murakami, H ;

Asou, N ;

Ino, T ;

Okamoto, T ;

Usui, N ;

Nishimura, M ;

Shinagawa, K ;

Fukushima, T ;

Taguchi, H ;

Morii, T ;

Mizuta, S ;

Akiyama, H ;

Nakamura, Y ;

Ohshima, T ;

Ohno, R .

LEUKEMIA, 2002, 16 (07) :1259-1266

[74] TGF-β induces degradation of TAL1/SCL by the ubiquitin-proteasome pathway through AKT-mediated phosphorylation [J].

Terme, Jean-Michel ;

Lhermitte, Ludovic ;

Asnafi, Vahid ;

Jalinot, Pierre .

BLOOD, 2009, 113 (26) :6695-6698

[75] Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate [J].

Thomas, DA ;

Faderl, S ;

Cortes, J ;

O'Brien, S ;

Giles, FJ ;

Kornblau, SM ;

Garcia-Manero, G ;

Keating, MJ ;

Andreeff, M ;

Jeha, S ;

Beran, M ;

Verstovsek, S ;

Pierce, S ;

Letvak, L ;

Salvado, A ;

Champlin, R ;

Talpaz, M ;

Kantarjian, H .

BLOOD, 2004, 103 (12) :4396-4407

[76]

THOMAS DA, 2007, BLOOD 1, V110, pA831

[77]

Thomas DA, 2009, BLOOD, V114, P344

[78] Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia [J].

Thomas, Deborah A. ;

O'Brien, Susan ;

Jorgensen, Jeffrey L. ;

Cortes, Jorge ;

Faderl, Stefan ;

Garcia-Manero, Guillermo ;

Verstovsek, Srdan ;

Koller, Charles ;

Pierce, Sherry ;

Huh, Yang ;

Wierda, William ;

Keating, Michael J. ;

Kantarjian, Hagop M. .

BLOOD, 2009, 113 (25) :6330-6337

[79] Outcome of treatment in adults with acute lymphoblastic leukemia:: Analysis of the LALA-94 trial [J].

Thomas, X ;

Boiron, JM ;

Huguet, F ;

Dombret, H ;

Bradstock, K ;

Vey, N ;

Kovacsovics, T ;

Delannoy, A ;

Fegueux, N ;

Fenaux, P ;

Stamatoullas, A ;

Vernant, JP ;

Tournilhac, O ;

Buzyn, A ;

Reman, O ;

Charrin, C ;

Boucheix, C ;

Gabert, J ;

Lhéritier, V ;

Fiere, D .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) :4075-4086

[80] Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) [J].

Topp, Max S. ;

Zugmaier, Gerhard ;

Goekbuget, Nicola ;

Kufer, Peter ;

Goebeler, Mariele ;

Klinger, Matthias ;

Degenhard, Evelyn ;

Baeuerle, Patrick A. ;

Schmidt, Margit ;

Nagorsen, Dirk ;

Neumann, Svenja ;

Horst, Heinz A. ;

Raff, Thorsten ;

Viardot, Andreas ;

Stelljes, Matthias ;

Schmid, Mathias ;

Ottmann, Oliver G. ;

Burmeister, Thomas ;

Einsele, Hermann ;

Riethmueller, Gert ;

Hoelzer, Dieter ;

Bargou, Ralf C. .

BLOOD, 2009, 114 (22) :346-346

← 1 2 3 4 5 6 7 8 9 →